{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '8.3.1.', 'Dose Modification', 'The general approach regarding missed doses of cemiplimab (eg, due to AEs) is \"time marches', 'on.\" Missed doses of systemic therapy will not be made up, unless 3 business days from the', 'scheduled date.', 'The planned dose and schedule is a 350 mg flat dose of cemiplimab IV over approximately', '30 minutes (+10 minutes) Q3W. Patients will generally remain on the assigned dosage of', 'cemiplimab throughout the course of study treatment. The general approach to cemiplimab', 'toxicity management is dose interruption rather than dose modification. Cemiplimab treatment', 'may be held at any time upon occurrence of a treatment-related AE. General guidelines for', 'cemiplimab treatment modifications due to treatment-related AEs and irAEs are provided in', 'Table 4 and Table 5. These recommendations should be seen as guidelines, and the treating', 'physician should exercise clinical judgment based on the symptoms and condition of the individual', 'patient. For additional information regarding irAEs, reference Section 8.3.2 and Appendix 2.', 'Acute infusion reactions to cemiplimab are discussed separately in Section 8.7.', 'Regeneron Pharmaceuticals, Inc.', 'Page 72 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Table 4:', 'General Guidelines for Cemiplimab Treatment Modifications or', 'Discontinuations Due to Adverse Events', 'Hold', 'Restarting', 'Toxicity', 'Grade', 'Treatment?', 'Criteria', 'Discontinuation Criteria', 'Hematological Toxicity (other', '1, 2, 3', 'No', 'N/A', 'N/A', 'than grade 3 thrombocytopenia', 'greater than 7 days or associated', 'with bleeding)', '4', 'Yes', 'Toxicity', 'Toxicity does not resolve', 'resolves to', 'within 84 days of last', 'grade 1 or', 'infusion', 'baseline', 'Permanent discontinuation', 'should be considered for', 'any severe or life-', 'threatening event', 'Grade 3 thrombocytopenia', '3', 'Yes', 'Toxicity', 'Toxicity does not resolve', 'greater than 7 days or associated', 'resolves to', 'within 84 days of last', 'with bleeding', 'grade 1 or', 'infusion', 'baseline', 'Permanent discontinuation', 'should be considered for', 'any severe or life-', 'threatening event', 'Nonhematological Toxicity', '1', 'No', 'N/A', 'N/A', 'NOTE: Exceptions to be treated as', '2', 'Consider', 'Toxicity', 'Toxicity does not resolve', 'for Grade 1 toxicity:', 'withholding for', 'resolves to', 'within 84 days of last', 'persistent', 'grade 0-1 or', 'infusion', 'Grade 2 alopecia', 'symptoms', 'baseline', 'Grade 2 fatigue', 'Clinically insignificant', 'lab abnormality not', 'meeting AE criteria', '3', 'Yes', 'Toxicity', 'Toxicity does not resolve', 'resolves to', 'within 84 days of last', 'grade 0-1 or', 'infusion', 'baseline', '4', 'Yes', 'N/A', 'Patient must be', 'discontinued', 'Regeneron Pharmaceuticals, Inc.', 'Page 73 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Table 5:', 'General Treatment Hold Guidelines for Immune Related Adverse Events', 'Severity', 'Withhold/Discontinue Treatment?', 'Supportive Care', 'Grade 1', 'No action', 'Provide symptomatic treatment', 'Grade 2', 'May withhold treatment', 'Consider systemic corticosteroids in addition to', 'appropriate symptomatic treatment', 'Grade 3', 'Withhold treatment', 'Systemic corticosteroids are indicated in addition to', 'Grade 4', 'Discontinue if unable to reduce', 'appropriate symptomatic treatment. May utilize 1', 'corticosteroid dose to <10 mg per', 'to 2 mg/kg prednisone or equivalent per day.', 'day prednisone equivalent within 12', 'Steroid taper should be considered once symptoms', 'weeks of toxicity', 'improve to Grade 1 or less and tapered over at least', '4 weeks.', 'For any severe (grade 3-4) irAE, if symptoms', 'worsen or do not improve on adequate', 'corticosteroids within 48 to 72 hours, consider', 'adding additional immunosuppressive agents (to be', 'selected from agents such as infliximab,', 'cyclophosphamide, cyclosporine, mycophenolate', 'mofetil). Referral of the patient to a specialized unit', 'for assessment and treatment should be considered.', 'In the limited circumstances in which cemiplimab dose modifications are called for in the toxicity', 'management guidelines, the dose reductions will be as per Table 6. The medical monitor should', 'be notified of dose reductions.', 'Table 6:', 'Cemiplimab Dose Reductions', 'Dose Level', 'Reduction Order', 'Dose', 'Dose Level - -1', 'First dose reduction', '120 mg flat dose cemiplimab Q3W', 'Dose Level -2', 'Second dose reduction', '60 mg flat dose cemiplimab Q3W', 'A patient who requires dose reduction below dose level -2 will be permanently discontinued from', 'the study.', '8.3.2.', 'Immune-Related Adverse Events (irAEs)', 'Investigators must be extremely vigilant and be ready to intervene early in the management of', 'irAEs, as the onset of symptoms of irAEs (eg, pneumonitis) may be subtle. Detailed guidance of', 'management of irAEs is provided in Appendix 2. In the event of irAEs that are not addressed in', 'Appendix 2, general guidance is provided in Table 5. The recommendations in Table 5 and', 'Appendix 2 should be seen as guidelines, and the treating physician should exercise clinical', 'judgment based on the symptoms and condition of the individual patient.', 'NOTE: Regarding irAEs, for any AE that is of a type known to be potentially immune-related', '(eg, rash, colitis, elevated transaminases, endocrine), but is deemed not to be an irAE by the', 'investigator, the sponsor may request additional information.', 'Based on the emerging safety profile of cemiplimab and other antibodies targeting the PD-1/PD-L1', 'axis (Weber 2015) (Naidoo 2015), the following working case definitions are provided to help', 'Regeneron Pharmaceuticals, Inc.', 'Page 74 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}